News > Press Release
Alzheimer's Disease Research
BrightFocus Foundation Statement on the Passing of Peter Davies, PhD
Written By: BrightFocus Editorial Staff
The following statement was issued by Diane Bovenkamp, PhD, BrightFocus Foundation Vice President for Scientific Affairs:
BrightFocus Foundation mourns the recent passing of Peter Davies, PhD. A globally-recognized leader in research on Alzheimer’s and related dementia, Dr. Davies served on our Scientific Review Committee for this field for 11 years, including six years as its chair.
Through this role, Dr. Davies left a lasting legacy of pivotal, early career support for a generation of promising Alzheimer’s researchers, many of whom have gone on to achieve great scientific distinction and impact. He believed strongly in the power of innovation, opening up the Alzheimer’s research field to new and more diverse approaches to ending this disease.
Peter Davies was a scientific pioneer, a generous mentor, and a catalyst for innovation and collaboration. He will be greatly missed.
About BrightFocus Foundation
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $300 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
News
Related Articles and Information
Article
Shaping the Future of National Alzheimer’s Research Priorities
BrightFocus Foundation’s VP of Scientific Affairs helped set national research priorities at the federal Alzheimer’s Disease-Related Dementias Summit, influencing how billions in NIH funding will advance dementia research and care.
Article
FDA Approves At-Home Injectable Leqembi for Alzheimer’s
New formulation of Leqembi allows weekly at-home injections, reducing the need for hospital visits.
Article
Breaking News Dispatch: New Discoveries in Alzheimer’s Prevention, Diagnosis, and Treatment
From lifestyle changes that protect memory and cutting‑edge blood tests to promising long‑term treatment results, promising new developments in Alzheimer’s research were unveiled at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto.
Press Release
BrightFocus Foundation and Dementia Alliance North Carolina Partner to Advance Alzheimer’s Innovation
The partnership supports an outstanding researcher at UNC Chapel Hill who is advancing novel gene therapy strategies for Alzheimer’s disease.
Press Release
BrightFocus Foundation Receives $3.2 Million Grant for Alzheimer’s Research
BrightFocus Foundation received a $3.2 million grant from an anonymous foundation to support 12 new Alzheimer’s Disease Research grants.
Press Release
Investment in Alzheimer’s Research Today Will Yield Health Benefits for the Next Generation of Adults With Down Syndrome, New Report Finds
Report shows that boosting research investment into the wellbeing of adults with Down syndrome would improve their quality-of-life outcomes, reduce caregiving costs, and extend the lifespan of adults with Down syndrome by five years.
